Harada Arisa, Oguchi Masahiko, Terui Yasuhito, Takeuchi Kengo, Igarashi Masahiro, Kozuka Takuyo, Harada Ken, Uno Takashi, Hatake Kiyohiko
Radiation Oncology Department, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Kouto-ku, Tokyo 135-8550, Japan
Radiation Oncology Department, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Kouto-ku, Tokyo 135-8550, Japan.
J Radiat Res. 2016 Jul;57(4):412-7. doi: 10.1093/jrr/rrw011. Epub 2016 Mar 23.
The aim of this study was to evaluate the initial treatment results and toxicities of radiation therapy for patients with early stage low-grade follicular lymphoma (FL) arising from the duodenum. We reviewed 21 consecutive patients with early stage duodenal FL treated with radiation therapy between January 2005 and December 2013 at the Cancer Institute Hospital, Tokyo. The characteristics of patients were: median age 62 years (range, 46-79 years), gender (male, 6; female, 15), clinical stage (I, 20; II1, 1), histological grade (I, 17; II, 4). All patients were treated with radiation therapy alone. The median radiation dose was 30.6 Gy (range, 30.6-39.6) in 17 fractions. The involved-site radiation therapy was delivered to the whole duodenum. The median follow-up time was 43.2 months (range 21.4-109.3). The 3-year overall survival (OS), relapse-free survival (RFS) and local control (LC) rates were 94.7%, 79.3% and 100%, respectively. There were four relapses documented outside the treated volumes: two in the gastrointestinal tract (jejunum, terminal ileum), one in an abdominal lymph node (mesenteric lymph node) and one in the bone marrow. None died of the disease; one death was due to acute myeloid leukemia. No toxicities greater than Grade 1 were observed during treatment and over the follow-up time. The 30.6 Gy of involved-site radiation therapy provided excellent local control with very low toxicities. Radiation therapy could be an effective and safe treatment option for patients with localized low grade FL arising from the duodenum.
本研究的目的是评估十二指肠原发性早期低度滤泡性淋巴瘤(FL)患者接受放射治疗的初始治疗效果及毒性。我们回顾了2005年1月至2013年12月期间在东京癌症研究所医院接受放射治疗的21例连续性十二指肠原发性早期FL患者。患者特征如下:年龄中位数62岁(范围46 - 79岁),性别(男性6例;女性15例),临床分期(I期20例;II1期1例),组织学分级(I级17例;II级4例)。所有患者均仅接受放射治疗。中位放射剂量为30.6 Gy(范围30.6 - 39.6),分17次给予。受累部位放射治疗范围为整个十二指肠。中位随访时间为43.2个月(范围21.4 - 109.3)。3年总生存率(OS)、无复发生存率(RFS)和局部控制率(LC)分别为94.7%、79.3%和100%。有4例复发发生在治疗野之外:2例发生在胃肠道(空肠、回肠末端),1例发生在腹部淋巴结(肠系膜淋巴结),1例发生在骨髓。无患者死于该疾病;1例死亡原因是急性髓系白血病。治疗期间及随访期间未观察到大于1级的毒性反应。30.6 Gy的受累部位放射治疗提供了极佳的局部控制,且毒性极低。放射治疗对于十二指肠原发性局限性低度FL患者可能是一种有效且安全的治疗选择。